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ABST RACT

Oral manifestations are present both in Cushing's syndrome and in adrenal
insufficiency. Possible oro-dental pathology in patients with Cushing's
syndrome include jawbone loss, tooth loss, and periodontal diseases.
Professional societies did not include Cushing's syndrome as being part of
systemic diseases associated with loss of periodontal supporting tissues. The
comorbidities of Cushing's syndrome such as obesity, osteoporosis, and
diabetes are conditions that influence periodontal attachment apparatus. In
patients with adrenal primary insufficiency, the most specific sign is the
melanic pigmentation of the skin and mucosal surfaces due to increments of
corticotropin and pro-opiomelanocortin peptide levels that occur as a result
of decreased cortisol feedback. The oral mucosa develops black plaques that
can also be present on the gums, palate, tongue, and lips. The pallor may
occur in patients with adrenocortical insufficiency secondary to
corticotropin deficiency. Patients with primary adrenal insufficiency need to
increase their glucocorticoid doses during physical activity, intercurrent
illnesses, surgery, and medical procedures. Current evidence indicates that
routine, nonsurgical, or minor surgical procedures do not need supplemental
glucocorticoids in diagnosed patients who are in a stable condition.
However, for major oral surgery, glucocorticoid supplementation is
necessary for the surgery day and for at least one postoperative day.

Introduction
Periodontal diseases, also known as gum diseases, are
being detected more frequently in patients undergoing
routine dental control. This type of pathology is linked to
several metabolic imbalances but can also originate from
hormone level fluctuations. Understanding the
connection between glucocorticoid levels and several
characteristic manifestations of oro-dental pathologies
can help dentists develop better therapeutic protocols.
The endocrinologist and the dentist need to be familiar
with the oral manifestations of endocrine conditions and
must have good communication to maintain patient oral
health in Cushing's syndrome and to prevent a possible
adrenal crisis in the case of major oral surgery in patients
with adrenal insufficiency.
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Discussions
Cushing's syndrome
Cushing's syndrome is a disorder characterized by
chronic exposure to glucocorticoid excess. The etiology of
this syndrome includes exogenous or endogenous
hypercortisolism [1]. The exogenous (or iatrogenic)
Cushing's syndrome is the most common cause of
hypercortisolism and is generated by administration of
supraphysiologic doses of steroid therapy for
inflammatory, autoimmune, or neoplastic disorders [2].
The endogenous Cushing's syndrome includes
adrenocorticotropic hormone (ACTH) dependent or ACTH
independent forms. ACTH dependent Cushing's syndrome
is generated by ACTH production by a pituitary adenoma
or nonpituitary tumors and excess of corticotropinreleasing hormone producing tumors [3]. Ectopic ACTH
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production derives from pulmonary carcinoid tumor,
pancreatic or thymic neuroendocrine tumors, medullar
thyroid cancer, pheochromocytoma etc. [4]. Păun et al.
described ectopic ACTH-dependent Cushing's syndrome
arising from a Meckel diverticulum [5]. ACTH-dependent
Cushing's syndrome accounts for 80 % of cases [1]. With
a much lower frequency (15-20%), ACTH-independent
Cushing's syndrome can by generated by adrenal unilateral
tumors, macronodular adrenal hyperplasia, or primary
pigmented nodular adrenal disease [1].
The most common signs of disease are represented by
progressive weight gain, moon face, supraclavicular and
dorsocervical fat pads, hirsutism or alopecia, facial
plethora, violaceous striae, acne, depression, and mania.
The clinical presentation is influenced by age, sex, and the
severity and duration of hypercortisolism [1,6,7].
However, it should be mentioned that no signs or
symptoms are pathognomonic. The chronic glucocorticoid
exposure is associated with comorbidities such as obesity,
cardiovascular diseases, hypercoagulability, impaired
glucose tolerance or diabetes mellitus, dyslipidemia,
osteoporosis, and increased susceptibility to infection with
common or unusual agents [8].
Possible oro-dental pathology in patients with
Cushing's syndrome can include jawbone loss, tooth loss,
and periodontal diseases. The jawbone supports the teeth;
when bone becomes less dense the tooth mobility is
increased [9]. Periodontal disease is a set of inflammatory
conditions affecting the tissues surrounding the teeth. In
2017, the “American Academy of Periodontology (AAP)
and the European Federation of Periodontology (EFP)”
recommended a classification for periodontal and perimplant disease and conditions. Periodontal disease and
conditions comprise three major categories [10]:
“1. Periodontal health and gingival diseases: periodontal
and gingival health, gingivitis caused by biofilm,
gingivitis not caused by biofilm.
2. Periodontitis: necrotizing diseases, periodontitis,
periodontitis as a manifestation of systemic disease.
3. Other conditions affecting the periodontium: systemic
diseases affecting the periodontal supporting tissues,
periodontal abscess, or periodontal and endodontic
lesions, mucogingival deformities and conditions,
traumatic occlusal forces, tooth, and prosthesis related
factor.”
The peri-implant disease and conditions include periimplant health, peri-implant mucositis, peri-implantitis and
peri-implant soft- and hard-tissue deficiencies [10].
The proceedings of the workshop conducted by AAP
and EFP did not include Cushing's syndrome among the
systemic diseases associated with loss of periodontal
supporting tissues. Comorbidities of Cushing's syndrome
such as obesity, osteoporosis, and diabetes are mentioned
among the conditions that affect periodontal attachment
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apparatus [11]. In Cushing's syndrome, the prevalence of
obesity varies between 70% and 95%, that of osteoporosis
between 50%-80%, and that of diabetes mellitus between
20%-50% [1,12]. The possible mechanisms by which
obesity increases periodontitis, periodontal disease
progression, and loss of periodontal attachment risk
include immune response and increased production of
proinflammatory cytokines. A systematic review regarding
the association between obesity and periodontitis was
published in 2010 in the Journal of Periodontology by
Chaffee and Weston. After systematic analysis of
databases, the authors conclude that obesity increases
susceptibility to infection and “obesity is a risk factor for
periodontal disease or that periodontitis might increase the
risk of weight gain” [13]. The likelihood of periodontitis in
obese patients varies between 50% to 80% compared with
normal-weight subjects, and the risk is higher among obese
women compared with obese men [13,14]. The response to
periodontal treatment does not differ for obese patients
versus normal-weight subjects [15].
Osteoporosis is associated with a higher prevalence of
alveolar bone loss but the association with periodontitis is
not clear [11]. Beetaka and coworkers published in 2013 in
Dental Research Journal a study about the oral health of
patients under long-term corticosteroid therapy. 100
patients who received corticosteroid therapy for a
minimum of 3-months duration and 100 healthy subjects
were included in the study. The results showed that
“Patients on steroids exhibited significantly higher levels
of candidiasis and clinical attachment loss of the
periodontal ligament, probing pocket depth. Bone density
was significantly lower in the study group than that in the
control group. Random blood glucose was significantly
higher and significant lower levels of calcium were
observed in patients on steroids” [16].
Oral health in patients on inhaled corticoid therapy
was investigated in 30 patients with chronic obstructive
pulmonary disease by Komerik et al. Results were
compared with those of 30 healthy subjects. The study
revealed that in patients on steroid treatment, bone density
of the mandible was lower than in the control group, and
the patients had more missing teeth [17]. Bisphosphonates
are the first line options for treatment of osteoporosis but
do not directly address the decreased bone characteristic of
the glucocorticoid-induced bone disease [18]. Treatment
with bisphosphonates can generate osteonecrosis of the
jaw, typically diagnosed after an invasive procedure, and
associated with poor dental hygiene and infection. Other
risk factors for bisphosphonates-associated osteonecrosis
of the jaw are cancer and anti-cancer therapy, duration of
exposure to therapy, glucocorticoids, pre-existing dental or
periodontal disease, tobacco and alcohol abuse, etc.
[18,19]. Before prescribing bisphosphonates, the
“American Society for Bone and Mineral Research”
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recommends communication between physicians and
dentists, informing patients about the benefits and risks of
bisphosphonates, including the risk for developing jaw
osteonecrosis and the signs and symptoms of jaw
osteonecrosis (pain, swelling, suppuration, soft tissue
ulceration, intra-or extraoral sinus tracks, loosening of
teeth). Patients in treatment with bisphosphonates should
be encouraged to maintain good oral hygiene and to have
regular dental visits and to report any oral problems [19].
There is information on potential pathways which
support the association between diabetes mellitus and
periodontitis. The presence of hyperglycemia in gingival
crevicular fluid can generate the growth of certain bacterial
species in the subgingival environment which may increase
susceptibility to periodontitis. The hyperinflammatory
response to bacterial challenge can generate
hyperinflammatory response of monocytes, increased
release of proinflammatory cytokines, and oxidative stress
reactions [11,20]. In patients with type 1 diabetes mellitus
there
is evidence
that monocytes
have
a
hyperinflammatory phenotype and cells are responding to
periodontal bacteria, producing higher levels of interleukin
1β, prostaglandin E2, and tumor necrosis factor alpha,
suggesting that this phenomenon may be involved in the
pathogenesis of periodontitis in diabetes [21,22].
Increasing nonenzymatic protein glycation characteristic
of diabetes mellitus can generate the advanced glycation
end products (AGEs). Several studies have shown that
AGEs contribute to the diabetic complications and,
regarding the periodontal tissue, AGEs contribute to
increase of alveolar loss in diabetic mice [23]. Diabetes is
a redox imbalance disease [24-26]. The oxidative stress is
involved in the pathogenesis of diabetes complications and
there is evidence showing increased local and systemic
alterations in the redox balance of periodontitis [27].
Diagnostic of Cushing's syndrome. In 2008, the
Endocrine Society Guidelines recommended exclusion of
exogenous doses of glucocorticoid therapy before
conducting biochemical testing. Testing for Cushing's
syndrome is recommended in the following situations:
patients with unusual features for age, with multiple and
progressive features predictive of the syndrome, adrenal
incidentaloma, or children with decreased height and
increased weight. For the initial testing, the Endocrine
Society guidelines recommend urine free cortisol, late–
night salivary cortisol, 1-mg overnight dexamethasone
suppression test, and long low dose dexamethasone
suppression test (2 mg). In individuals with abnormal test
results, the following investigations are recommended:
random serum cortisol or ACTH levels, urinary 17ketosteroids, pituitary and adrenal imaging, and 8 mg
dexamethasone suppression test [28].
Management of Cushing's syndrome. The Clinical
Practice Guidelines of the Endocrine Society published in

2015 in “The Journal of Clinical Endocrinology &
Metabolism”, recommend that effective treatment should
include normalization of cortisol levels or action.
“Surgical resection of the causal lesion(s) is generally the
first-line approach. The choice of second-line treatments,
including medication, bilateral adrenalectomy, and
radiation therapy (for corticotrope hormone), must be
individualized to each patient” [29]. Treatment of
comorbidities is important to reduce mortality.
Management of exogenous Cushing's syndrome involves:
dose and duration of glucocorticoid therapy should be kept
as low as possible, pulse glucocorticoid therapy should be
used only when absolutely indicated, use of highly potent
and long-acting glucocorticoid should be restricted to acute
setting only, and short-acting glucocorticoid is preferred
for long-term treatment [30].
Adrenocortical insufficiency
Adrenal insufficiency can be generated by destruction
of adrenal cortex (primary adrenocortical insufficiency) or
can be secondary to pituitary or hypothalamic diseases.
The condition can manifest as a chronic or acute form
[31,32]. Primary adrenal insufficiency is a relatively rare
disease. Its etiology includes autoimmune adrenalitis,
infectious diseases (tuberculosis, fungal, viral), neoplastic
diseases, adrenal hemorrhage or thrombosis, drug,
infiltration, and neonatal or genetic conditions. Secondary
adrenocortical insufficiency can be generated by pituitary
or metastatic tumors, craniopharyngioma, pituitary surgery
or irradiation, infiltration, empty sella syndrome, Sheehan
syndrome, lesions of the pituitary stalk, hypothalamic
tumors, and exogenous corticosteroids [33]. In primary
adrenal insufficiency there is a deficiency of the
glucocorticoid and mineralocorticoid hormones. Cortisol
deficiency manifests as fatigue, anorexia, nausea, weight
loss, diminished resistance to infection, and
hyperpigmentation as a consequence of cessation of
inhibition at pituitary level with increments of ACTH and
melanocyte stimulating hormone. Aldosterone deficiency
generates sodium and liquid depletion, increased diuresis,
and secondary hypotension and dehydration. In secondary
adrenocortical insufficiency, the mineralocorticoid
function is preserved [34].
Oro-dental pathology in patients with adrenal
insufficiency. The most specific sign of primary adrenal
insufficiency is the melanic pigmentation of the skin and
mucosal surfaces as a consequence of increments of
corticotropin and pro-opiomelanocortin peptide levels that
result from decreased cortisol feedback. The oral mucosa
develops black plaques that can be also present on the
gums, palate, tongue and lips. Pallor may occur in patients
with secondary adrenocortical insufficiency secondary to
corticotropin deficiency [35,36].
Diagnostic of adrenal insufficiency. Serum cortisol is
a test used in the screening and diagnosis of adrenal
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insufficiency and can be measured in early morning
between 08.00 and 09.00 h. Betterle Cet al. mention that
“Hormonal pattern of morning plasma cortisol
concentrations of less than 3 μg/dl (83 nmol/liter) are
indicative of clinical adrenal insufficiency whereas
concentrations of more than 19 μg/dl (525 nmol/liter) rule
out the disorder“ [33]. Measurement of serum cortisol may
represent the first laboratory test in patients evaluated for
hypothalamic, pituitary, and adrenal insufficiency [37].
Determining values of plasma ACTH is used to
differentiate between primary and secondary adrenal
insufficiency. The Clinical Guidelines Subcommittee of
the Endocrine Society recommends confirmatory testing
with corticotropin for diagnosis of primary adrenal
insufficiency. The guidelines suggest the standard dose of
250 ug for adults, 15 μg/kg for infants and 125 μg for
children under 2 years of age, in intravenous
administration. The low dose (1μg) corticotropin test is
recommended when the substance itself is in short supply.
To assess the presence of mineralocorticoid deficiency, the
simultaneous measurement of plasma renin and
aldosterone is recommended. After an endocrinological
diagnosis has been established by hormonal testing, the
etiology of the disease should be determined [38].
Management of adrenal insufficiency. The Clinical
Guidelines of the Endocrine Society published in 2016
recommend glucocorticoid and mineralocorticoid
replacement in all patients with confirmed adrenal
insufficiency. In adults, glucocorticoid replacement can be
achieved by administering hydrocortisone 15-25 mg/day or
cortisone acetate 20-35 mg/day in two or three divided
doses administered via oral route; the highest dose should
be given in the morning. In patients with reduced
compliance an alternative is prednisolone 3-5 mg once or
twice per day administrated orally. In children,
glucocorticoid replacement can be achieved by oral intake
of hydrocortisone in three or four doses, with total starting
dose of 8 mg/m2 body surface area. It is recommended to
monitor glucocorticoid therapy by clinical assessment.
Patients with primary adrenal insufficiency need to
increase glucocorticoid doses during physical activity,
intercurrent illnesses, surgery, and medical procedures. In
adults, mineralocorticoid replacement can be achieved by
administering fludrocortisones with a starting dose of 50100 μg/day without restricted salt intake. In children, the
starting dose is of 100 μg/day with supplements of sodium
chloride in the newborn up to the age of 12 months.
Dehydroepiandrosterone
replacement
may
be
recommended in women with low libido, depressive
symptoms, and asthenia which has not been optimized by
glucocorticoid and mineralocorticoid treatment. In the
absence of a beneficial effect of therapy after 6 months, the
dehydroepiandrosterone should be discontinued [38,39].
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The management of adrenal insufficiency secondary to
hypothalamic-pituitary failure conventionally is based on
the long-term replacement of hydrocortisone (20 mg in the
morning and 10 mg in the evening); the mineralocorticoid
replacement is not required in patients with secondary
adrenal insufficiency [40]. Education of the patient is
essential for the management of this condition. Patients
should be instructed to increase the dosage of
glucocorticoids during intercurrent illness, fever, and
stress, and promptly identify suggestive signs and
symptoms of acute adrenal crisis is especially important.
The acute adrenal crisis is an emergency that requires
prompt recognition and therapy. Symptoms of an acute
adrenal crisis are major impairment of general health,
hypotension, nausea, vomiting, abdominal pain, and
impaired cognitive function. Treatment of patients with
possible acute adrenal crisis must be initiated immediately
and should not be delayed by diagnostic investigations.
Important is intravenous administration of 100 mg
hydrocortisone followed by 100-300 mg/day as continuous
infusion or frequent intravenous or intramuscular boluses
every 6 hours, isotonic saline infusion, and treatment of the
precipitating condition [38, 39].
Dental management of the patients with adrenal
insufficiency. In dental practice, patients experience pain
or stress generated by procedures, and anxiety control is
important for the dental management of these patients [39].
Current evidence indicates that the routine, nonsurgical, or
minor surgical procedures do not need supplemental
glucocorticoids in diagnosed patients in a stable condition
[38]. Invasive procedures increase the plasma cortisol
levels during and after a surgery. In a review published in
2001 in the “Journal of the American Dental Association”,
Miller and coworkers mention that “For major oral
surgical stress (for example, multiple extractions,
quadrant periodontal surgery, extraction of bony
impactions, osseous surgery, osteotomy, bone resections,
oral cancer surgery), surgical procedures involving the
use of general anesthetic, procedures lasting more than
one hour, or procedures associated with significant blood
loss, the glucocorticoid target is about 50 to 100 mg per
day of hydrocortisone equivalent for the day of surgery and
for at least one postoperative day“ [34]. The adrenal crisis
related to dental treatment is rarely mentioned in the
literature. Miller et al searched the literature from 1966 to
2000 for information that addressed adrenal insufficiency
and adrenal crisis in dentistry; 4 reports were identified
over 35 years [34, 41-44]. Features in 3 reports included
patients who had multiple extractions performed with
administration of general anesthetic or oral infection [30].
The authors identified four risk factors that contribute to
the risk of adrenal crisis during the perioperative period of
oral surgery: magnitude of surgery, general anesthetic,
health of the patient, and the degree of anxiety control; they
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concluded
that
perioperative
glucocorticoid
supplementation “can be prescribed in a more rationale
manner than is currently the case“ [34, 45].

Highlights
✓ Oro-dental pathology is linked to both glucocorticoid
excess and deficit.
✓ Identifying the specific periodontal symptoms
associated with either Cushing's syndrome or
adrenocortical insufficiency is essential for good
dental management in these particular patients.

Conclusions
Oral manifestations are present in the case of
glucocorticoid excess but also in the case of glucocorticoid
deficiency. The endocrinologist and the dentist need to be
familiar with the oral manifestations of these conditions
and must ensure good communication to maintain patient
oral health in Cushing's syndrome and prevent a possible
adrenal crisis in the case of major oral surgery in patients
with adrenal insufficiency.
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